IPC Appoints New President for 2023
The IPC Board of Directors is pleased to announce that it has named Hervé Bachelez, MD, PhD, as its newly appointed President, effective January 1, 2023.
Thursday, January 26, 2023
International Psoriasis Council
Menu
Advancing Knowledge. Enhancing Care.
Menu
Psoriasis News
THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results
Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami
Under the title, What’s Next in Psoriasis? From Maintenance to Disease Modification, the 2022 IPC Think Tank scientific symposium was held on Friday, December 9th, in Miami, Florida. Read the full report or a summary of the five psoriasis focused sessions.
Tuesday, January 24, 2023
Meet Our 2022 Volunteers of the Year
The IPC’s global network of experts generously volunteers their time every year to educate and train other physicians to better care for people with psoriasis. We would like to recognize our top three Councilors that went above and beyond in 2022 to support our work.
Friday, January 20, 2023
Prioritizing the Patient Perspective in Psoriasis Care and Communications
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making it a priority.
Wednesday, January 18, 2023
New Developments in Pediatric Psoriasis — And How to Help Parents Understand Them
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
Thursday, January 12, 2023
A Year in Review: Advancements in Psoriasis Care, Research, and Treatment
In 2022, the IPC advanced in the worldwide psoriasis community, ranging from multiple research efforts, education of dermatologists, and public awareness, reaching the patient communities. In addition to face-to-face events, the IPC has expanded its digital presence. Read some of IPC’s significant achievements from the past year and leave a comment letting us know what topics you want to see on the IPC website in the coming year!
Monday, January 9, 2023
New Corporate Member
IPC is pleased to welcome Aristea Therapeutics as a 2023 Bronze Level Corporate Member.
Thursday, January 5, 2023
Why a New Psoriasis Disease Severity Classification System Will Better Serve Psoriasis Patients
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion leaders agreed on a definition for each category of disease severity.
Tuesday, December 27, 2022
European Commission Approves SPEVIGO® (spesolimab) for Generalized Pustular Psoriasis (GPP) Flares
European Commission grants conditional marketing authorization based on the EFFISAYIL® 1 trial, which showed over half of the spesolimab-treated patients were free of pustules, one week after receiving a single dose. This decision builds on existing approvals in the United States and Japan.
Tuesday, December 20, 2022
Revised IPC Statement on COVID-19
This revised statement is based on expert opinion and should be interpreted in the context of local policies and emerging evidence.
Monday, December 19, 2022
Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Thursday, December 15, 2022
The Future of Treatment in Generalized Pustular Psoriasis
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and potentially life-threatening autoinflammatory disease.
Tuesday, December 6, 2022
Subscribe to the IPC Newsletter
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.